INDOCO2024-10-012024-12-31 INDOCO2024-10-012024-12-31 INDOCO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member INDOCO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member INDOCO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member INDOCO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member INDOCO2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2024-04-01 2025-03-31 2025-01-21 2025-01-13 INR Lakhs Third quarter 11:10:00 12:20:00 2025-01-21 2025-01-21 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Standalone 3729800000.00 42600000.00 3772400000.00 915400000.00 349400000.00 -222600000.00 907200000.00 140000000.00 247500000.00 1579000000.00 3915900000.00 -143500000.00 9900000.00 -133600000.00 -50400000.00 19100000.00 -31300000.00 0.00 -102300000.00 0.00 0.00 0.00 0.00 -102300000.00 -2200000.00 -104500000.00 0.00 0.00 184400000.00 2 -1.11 -1.11 0.00 0.00 -1.11 -1.11 1.The unaudited Standalone Results for the quarter and Nine months ended 31-12-2024 have been reviewed by the Audit Committee and approved by the Board of Director of the Company at its meeting held on 21st January, 2025. The Statutory Auditors have expressed an Unmodified Audit Opinion on these unaudited Standalone Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4.Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Qtr ended Qtr ended Qtr ended Nine mths Nine mths Year ended and Income 31.12.2024 30.09.2024 31.12.2023 ended ended 31.03.2024 from (Unaudited) (Unaudited) (Unaudited) 31.12.2024 31.12.2023 (Audited) Operations (Unaudited) (Unaudited) --------------------------------------------------------------------------------------------------------------------------------------- India 23,935 24,693 23,597 69,959 71,615 92,431 Outside India 12,556 14,765 21,241 45,412 61,066 83,764 ----------------------------------------------------------------------------------------------------------------------------- Total : 36,491 39,458 44,838 1,15,371 1,32,681 1,76,195 5. The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended 31st December, 2024. 6. (*) Exceptional items include consideration received Rs. 99.4 lacs for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 11709400000.00 119800000.00 11829200000.00 2625700000.00 1103100000.00 -190600000.00 2688000000.00 406500000.00 733700000.00 4237400000.00 11603800000.00 225400000.00 9900000.00 235300000.00 29300000.00 30900000.00 60200000.00 0.00 175100000.00 0.00 0.00 0.00 0.00 175100000.00 -6700000.00 168400000.00 0.00 0.00 184400000.00 2 1.90 1.90 0.00 0.00 1.90 1.90 OTHER EXPENSES 1392400000.00 RESEARCH & DEVELOPMENT EXPENSES 186600000.00 OTHER EXPENSES 3651200000.00 RESEARCH & DEVELOPMENT EXPENSES 586200000.00 -3000000.00 -9000000.00 -800000.00 -2300000.00